KLUS Pharma is a clinical-stage biotech focusing on the discovery and development of novel and safer antibody-based therapeutics to treat cancer and other life-threatening diseases.
Our Company
About KLUS
KLUS Pharma is the wholly-owned U.S. subsidiary of Kelun-Biotech, based in Cranbury, NJ. Kelun-Biotech is based in Chengdu, China.
Our Commitment
We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.
Our Pipeline
We have a rich pipeline of antibody-based therapeutics targeting solid tumors and clotting disorders, with multiple ongoing clinical trials.
Our Approach
Monoclonal Antibodies
Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.
Bispecific Antibodies
Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA.
Antibody-Drug Conjugates
Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR.
Mar 26, 2021
Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and UK company Ellipses Pharma Ltd. Announce a Licensing Agreement for Innovative Small Molecule Cancer Therapeutics
Mar 5, 2021
KLUS Pharma will attend BIO-Europe Spring Digital Event held on March 22-25, 2021.
Sep 2, 2020
The IND for KL-A289, an anti-LAG-3 monoclonal antibody, was recently approved by the NMPA in China.